Pars Plana Vitrectomy Combined with Internal Limiting Membrane Peeling to Treat Persistent Macular Edema after Anti-Vascular Endothelial Growth Factor Treatment in Cases of Ischemic Central Retinal Vein Occlusion

Yukari Shirakata, Tomoyoshi Fujita, Yuki Nakano, Fumio Shiraga, Akitaka Tsujikawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling in cases of ischemic central retinal vein occlusion (CRVO) where macular edema (ME) persisted after anti-vascular endothelial growth factor (anti-VEGF) treatment. Methods: Fifteen eyes with ischemic CRVO-related ME were included in the study. Nine were treated with panretinal photocoagulation after initial examination. Anti-VEGF agents were injected intravitreally. Persistent ME was treated with PPV combined with ILM peeling. During surgery, laser photocoagulation was further applied to the non-perfused area. Results: Mean retinal thickness gradually decreased after surgery (p = 0.024 at 6 months), although visual acuity did not improve significantly during the follow-up period (14.7 ± 11.6 months). Neovascular glaucoma subsequently developed in three cases and a trabeculectomy was performed in one case. Conclusion: In eyes with ischemic CRVO, PPV combined with ILM peeling contributed to a reduction in persistent ME. However, there was no significant improvement in visual acuity.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCase Reports in Ophthalmology
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Anti-vascular endothelial growth factor
  • Central retinal vein occlusion
  • Internal limiting membrane peeling
  • Macular edema
  • Pars plana vitrectomy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Pars Plana Vitrectomy Combined with Internal Limiting Membrane Peeling to Treat Persistent Macular Edema after Anti-Vascular Endothelial Growth Factor Treatment in Cases of Ischemic Central Retinal Vein Occlusion'. Together they form a unique fingerprint.

  • Cite this